Search results for "Coronavirus"
CDC and FDA weigh in on safety of bivalent vaccine; research examines COVID-19 sequelae, omicron variants
The CDC and FDA said an observed association of ischemic stroke with the Pfizer-BioNTech bivalent booster is very unlikely to represent a true clinical risk. New studies reported on symptoms a year after mild COVID-19 and estimated protection against the omicron variants.
https://immattersacp.org/weekly/archives/2023/01/24/2.htm
24 Jan 2023
New ACP living practice points, mortality data on COVID-19
The College offered recommendations on outpatient COVID-19 treatments. Three studies looked at shifts in mortality from COVID-19 at different times and places. An international study compared infections in health care workers with medical masks versus N95s.
https://immattersacp.org/weekly/archives/2022/11/29/2.htm
29 Nov 2022
Monoclonal antibodies appear safe as COVID-19 treatment during pregnancy
Pregnant patients who received monoclonal antibody treatments had no higher risk for adverse obstetric events but also no significant improvement on COVID-19-related outcomes, a retrospective study found.
https://immattersacp.org/weekly/archives/2022/11/15/2.htm
15 Nov 2022
Frequency of COVID-19 rebound debated in research, ACP/Annals forum
Two letters reported on SARS-CoV-2 viral rebound among patients taking nirmatrelvir-ritonavir. The latest ACP and Annals of Internal Medicine forum brought experts together to discuss this and other clinical challenges in COVID-19 prevention and management on Wednesday, Sept. 7.
https://immattersacp.org/weekly/archives/2022/09/13/2.htm
13 Sep 2022
New COVID-19 boosters authorized and recommended
The CDC has recommended the new formulations of the mRNA vaccines, targeted at the BA.4 and BA.5 lineages of the omicron variant, for adults and adolescents who last received a COVID-19 shot at least two months ago.
https://immattersacp.org/weekly/archives/2022/09/06/2.htm
6 Sep 2022
Register now for ACP and Annals of Internal Medicine's COVID-19 Forum X: Current Clinical Challenges in COVID-19 Prevention and Management
During the Sept. 7 virtual live event, a panel of experts will discuss current methods for preventing and managing SARS-CoV-2 infection.
https://immattersacp.org/weekly/archives/2022/08/30/4.htm
30 Aug 2022
Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine
Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
https://immattersacp.org/weekly/archives/2022/08/23/4.htm
23 Aug 2022
New COVID-19 vaccine authorized; reviews analyze myocarditis, drug treatments
The FDA gave the Novavax COVID-19 vaccine emergency use authorization for adults. One recent review found lower myocarditis risk with the Pfizer-BioNTech vaccine than the Moderna vaccine, and another looked at the strength of evidence supporting COVID-19 drug treatments.
https://immattersacp.org/weekly/archives/2022/07/19/4.htm
19 Jul 2022
Oral medications for COVID-19 underused among socially vulnerable, CDC study finds
By late May, the rate of prescriptions for molnupiravir and nirmatrelvir/ritonavir was twice as high in the highest-income U.S. ZIP codes as in the lowest, research showed. A CDC webinar on June 28 will discuss efforts to equitably distribute these treatments.
https://immattersacp.org/weekly/archives/2022/06/28/2.htm
28 Jun 2022
Nirmatrelvir/ritonavir rarely leads to rebound, doesn't help average-risk patients, studies find
A retrospective analysis found that symptom rebound occurred in less than 1% of high-risk COVID-19 patients treated with nirmatrelvir/ritonavir, while the manufacturer reported that the drug didn't show significant benefit in average-risk patients.
https://immattersacp.org/weekly/archives/2022/06/21/2.htm
21 Jun 2022